The tweet was deleted by the author.
But we saved everything 🙂.
Esperion Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference.
The event brings together leading companies and investors in the healthcare sector. Participation in the conference gives Esperion Therapeutics an opportunity to engage with industry stakeholders and showcase its latest developments. Details on the company’s presentations and agenda have not yet been disclosed.
Esperion recently unveiled new data on NEXLETOL from its CLEAR Outcomes study at the ACC Annual Scientific Session. Earlier this year, the company announced plans to acquire Corstasis Therapeutics, expanding its cardiovascular portfolio with Enbumyst nasal spray through the deal. These developments come as Esperion engages with investors and stakeholders at major industry events.